MET-097i: Research & Studies

Research Overview#

MET-097i has been evaluated in the VESPER clinical program. Phase 1 confirmed the ultra-long half-life of approximately 380 hours, and Phase 2b (VESPER-3) demonstrated 12.3% weight loss at 28 weeks using a weekly-to-monthly transition. Pfizer's $10 billion acquisition of Metsera reflects confidence in the asset and HALO platform.

VESPER-3 Phase 2b Results#

The VESPER-3 trial used a weekly-to-monthly transition protocol over 28 weeks. Weight loss of 12.3% was achieved, and PK modeling suggests that a direct monthly dose of 9.6 mg could reach approximately 16% weight loss with continued treatment. The biased GLP-1 agonism profile was associated with potentially reduced GI adverse events.

HALO Platform Validation#

The HALO technology demonstrated its ability to extend peptide half-life to levels unprecedented for GLP-1 agonists. The approximately 380-hour half-life is more than double that of semaglutide (~165 hours), establishing the feasibility of monthly peptide dosing.

Evidence Quality#

Research Evidence Context#

MET-097i belongs to the Metabolic category of research peptides. The research evidence for MET-097i spans multiple study types and endpoints. Researchers should evaluate the strength of evidence based on study design, sample size, and publication status when drawing conclusions about efficacy and safety.

Key Clinical Studies#

The following studies provide the clinical evidence base for MET-097i:

VESPER-3 Phase 2b Study of MET-097i in Adults with Obesity#

Authors: Metsera investigators (2025) — Conference presentation (Metsera/Pfizer)

Phase 2b study evaluating MET-097i in adults with obesity using a weekly-to-monthly transition dosing protocol over 28 weeks. The monthly dose achieved 12.3% weight loss with favorable tolerability.

Key Findings:

• 12.3% weight loss at 28 weeks with weekly-to-monthly transition
• PK modeling suggests 9.6 mg monthly could achieve ~16% weight loss
• Ultra-long half-life (~380 hours) confirmed in clinical setting
• Biased GLP-1 agonism with potentially reduced GI side effects

Limitations: Conference data; peer-reviewed publication pending; 28-week duration; transition protocol complicates interpretation; PK-based projections require clinical validation

VESPER Phase 1 Pharmacokinetic and Safety Study#

Authors: Metsera investigators (2024) — Conference presentation (Metsera)

Phase 1 study establishing the pharmacokinetic profile and safety of MET-097i. Confirmed the ultra-long half-life of approximately 380 hours supporting once-monthly dosing.

Key Findings:

• Half-life of approximately 380 hours confirmed
• Supports once-monthly subcutaneous dosing
• Acceptable safety profile in Phase 1

Limitations: Phase 1 with limited sample size; short-term safety data only

Evidence Quality Assessment#

The overall evidence level for MET-097i is classified as low. Available research includes limited clinical data, typically from small or early-phase studies. More rigorous clinical trials are needed to draw definitive conclusions.

Research Gaps and Future Directions#

The following gaps in the current evidence base for MET-097i have been identified:

• No Phase 3 data available
• Direct monthly dosing (without weekly transition) not clinically validated
• Long-term safety of ultra-long-acting GLP-1 agonism unknown
• No head-to-head comparison with semaglutide or tirzepatide
• Immunogenicity of HALO oligomer construct not fully characterized
• No data in type 2 diabetes populations

Addressing these research gaps will be important for establishing a more complete understanding of MET-097i's therapeutic potential and safety profile.

Related Reading#

• MET-097i overview and research guide
• MET-097i dosing protocols
• MET-097i molecular structure